No Data
No Data
Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –– Presentations highlight Avadel's continued commitment to address gaps in narcolepsy c
Avadel Pharmaceuticals: Appointment Effective May 17, 2024 >AVDL
Avadel Pharmaceuticals: Appointment Effective May 17, 2024 >AVDL
Express News | Avadel Pharmaceuticals Appoints Naseem Amin, M.d. to Its Board of Directors
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading
Telecoms stocks led European equities traded in the US as American depositary receipts slightly higher Tuesday morning, rising 0.15% to 1,420.65 on the S&P Europe Select ADR Index. From continental Eu
Avadel Gains for a Second Day as Analysts See It Prevailing in Case Vs Jazz/FDA
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher
European equities traded in the US as American depositary receipts kicked off the week higher in Monday morning, rising 0.62% to 1,421.16 on the S&P Europe Select ADR Index. From continental Europe, t
No Data